NeuroSense’s novel drug, PrimeC, aims to treat ALS by regulating microRNA synthesis, reducing neuroinflammation, and influencing iron accumulation. PrimeC is a novel formulation composed of unique doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, which aim to synergistically inhibit the progression of ALS. The drug mitigates the degeneration and inflammatory response of motor neurons, and has significantly outperformed conventional treatments in a zebrafish model of ALS.

NeuroSense’s preclinical studies showed outstanding results in zebrafish models of ALS. PrimeC was shown to improve motor performance, and recover the morphology of motor neurons, neuromuscular junction structures, and microglial cells. Following these promising results, NeuroSense conducted two clinical trials which have shown that the drug is safe and tolerable, with promising clinical signs. PrimeC has received an orphan drug status from the FDA and EMA, and is currently preparing for a robust Phase 2b/3 clinical trial.

There are many shared pathways between Parkinson’s disease and ALS, such as neuroinflammation, protein aggregation, mitophagy, excitotoxicity, oxidative stress, iron accumulation, and dysregulation of miRNAs. Therefore, we are working to develop a drug for Parkinson’s based on the foundations of our drug, PrimeC, for ALS. We have initiated the pre-clinical stage, testing StabiliC in in-vivo models of Parkinson’s, assessing morphological and functional effects, and plan to move into the clinical phase during 2023.

Due to the many shared pathways between neurodegenerative diseases, the hypothesis is that a disease-modifying drug for one, can lay the foundations for effective drugs for other neurodegenerative diseases. Therefore, we are working to develop a drug for Alzheimer’s based on the foundations of PrimeC. We have initiated the pre-clinical stage, testing CogniC in in-vitro models representing Alzheimer’s disease pathologies, and plan to continue into the clinical phase during 2022.

Skip to content